Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Target Price at $68.20

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $68.20.

LMAT has been the subject of several recent analyst reports. KeyCorp initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating for the company. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Barrington Research increased their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th.

Insider Activity

In other news, Director John A. Roush sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at $157,182. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director John A. Roush sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at $157,182. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO George W. Lemaitre sold 27,859 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $69.73, for a total transaction of $1,942,608.07. Following the completion of the transaction, the chief executive officer now directly owns 2,255,737 shares of the company’s stock, valued at approximately $157,292,541.01. The disclosure for this sale can be found here. Over the last quarter, insiders sold 114,036 shares of company stock valued at $7,873,749. 12.40% of the stock is currently owned by company insiders.

Institutional Trading of LeMaitre Vascular

Hedge funds have recently added to or reduced their stakes in the company. West Tower Group LLC raised its holdings in LeMaitre Vascular by 201.3% in the fourth quarter. West Tower Group LLC now owns 467 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 312 shares in the last quarter. Captrust Financial Advisors raised its holdings in LeMaitre Vascular by 555.3% in the first quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 522 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in LeMaitre Vascular in the third quarter valued at approximately $31,000. FMR LLC raised its holdings in LeMaitre Vascular by 111.7% in the first quarter. FMR LLC now owns 633 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 334 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in LeMaitre Vascular in the third quarter valued at approximately $38,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 1.0 %

Shares of NASDAQ LMAT opened at $63.26 on Wednesday. The firm has a 50-day simple moving average of $65.09 and a 200-day simple moving average of $57.85. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of 47.21, a price-to-earnings-growth ratio of 2.72 and a beta of 0.87. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.02. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The firm had revenue of $48.90 million during the quarter, compared to analysts’ expectations of $49.01 million. During the same period last year, the business earned $0.25 earnings per share. LeMaitre Vascular’s revenue was up 19.3% compared to the same quarter last year. As a group, equities research analysts expect that LeMaitre Vascular will post 1.66 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th were paid a $0.16 dividend. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.14. The ex-dividend date of this dividend was Wednesday, March 13th. This represents a $0.64 annualized dividend and a dividend yield of 1.01%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 47.76%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.